{"entity":{"id":"2032","kind":"year","name":"2032 in oncology","aka":["2032"],"tldr":"Everything OnCo dates to 2032: 5 entries, 3 landmarks and 2 expected dates. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.","summary":"5 dated entries in OnCo fall in 2032: 3 landmarks and 2 expected dates.\n\nOf those, 1 to the day, 1 to the month and 3 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.\n\nEverything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.","asOf":"2026-09-25","links":[],"tags":[],"related":["2031","2033"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Generated from every dated field in the corpus, not written by hand. The groups and the fields behind them are listed in src/lib/year-groups.ts; the reader is src/lib/years.ts."],"year":2032,"events":[{"group":"history","date":"2032","precision":"year","title":"The ctDNA strategy trials complete","note":"Colorectal cancer. CIRCULATE-US (NRG-GI008, 1,912 estimated participants) has a primary completion date of 10 March 2029 and the French CIRCULATE (1,980 estimated) of March 2032; N...","from":"colorectal","refs":["idea-crc-ctdna-de-escalation-beyond-stage-ii","nordicc","mrd-testing"]},{"group":"history","date":"2032","precision":"year","title":"The perioperative and first-line trials complete","note":"Lung cancer (all types). ADRIATIC's study completion is listed for 23 October 2026, IMpower010 for 31 August 2027, FLAURA2 for 30 September 2027, LAURA for 29 October 2027, MARIPOS...","from":"lung-cancer","refs":["lung-cancer-evidence-roadmap","alina","crown","mariposa"]},{"group":"history","date":"2032","precision":"year","title":"The platform and registry trials are due to complete","note":"Prostate cancer. ProBio's study completion is listed for December 2026, PSMAddition for 11 February 2027, CAPItello-281 for 31 March 2027, TALAPRO-3 for 28 August 2027, PROTEUS for...","from":"prostate","refs":["prostate-roadmap","psmaddition","capitello-281","nct04821622"]},{"group":"expected","date":"2032-03","precision":"month","title":"CIRCULATE (PRODIGE 70) primary completion: circulating tumour DNA-based adjuvant decision in stage II colon cancer (1,980 estimated participants; recruiting)","note":"Watch item on the Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherap...","from":"colorectal-roadmap","refs":["mrd-testing","ctdna","unicancer","idea-crc-ctdna-de-escalation-beyond-stage-ii"]},{"group":"expected","date":"2032-03-01","precision":"day","title":"NICHE platform primary completion: neoadjuvant checkpoint inhibition and novel combinations in early-stage colon cancer (353 estimated participants; recruiting)","note":"Watch item on the Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherap...","from":"colorectal-roadmap","refs":["niche-2","nivolumab","ipilimumab","nki"]}]},"route":"/years/2032/","neighbours":{"year":[{"id":"2031","kind":"year","name":"2031 in oncology","route":"/years/2031/"},{"id":"2033","kind":"year","name":"2033 in oncology","route":"/years/2033/"}]}}